Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.40 |
| ▸ | NPFFR1 | Q9GZQ6 | 1/20 | 0.39 |
| ▸ | NPFFR2 | Q9Y5X5 | 1/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.39 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18982241 | 0.95 | KMT2A (0.49) | KMT2AEPHX2MALT1FABP7FABP5 | |
| SCHEMBL27072523 | 0.91 | KMT2A (0.51) | KMT2AEPHX2CASP3 | |
| SCHEMBL26352259 | 0.91 | KMT2A (0.51) | KMT2AEPHX2CASP3 | |
| SCHEMBL30099527 | 0.90 | KMT2A (0.53) | KMT2AEPHX2MALT1NPFFR1NPFFR2 | |
| SCHEMBL19931854 | 0.85 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL29616475 | 0.85 | KMT2A (0.54) | KMT2AEPHX2CASP3 | |
| SCHEMBL16006885 | 0.84 | KMT2A (0.46) | KMT2AEPHX2MALT1MDM2CASP3 | |
| SCHEMBL29400357 | 0.84 | KMT2A (0.54) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL22860768 | 0.84 | KMT2A (0.54) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL17665039 | 0.83 | KMT2A (0.62) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20210299271-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2021-09-30 | — | — | US | disclosed |
| US-10988531-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | IMMUNOGEN, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| EP-3188733-B1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | IMMUNOGEN, INC. | 2016-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11732038-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | KMT2A 634/4885EPHX2 124/4885MALT1 1122/4885 |
| US-10988531-B2 | Conjugates comprising cell-binding agents and cytotoxic agents | PCNA, EPCAM, MKI67 | KMT2A 634/4885EPHX2 124/4885MALT1 1122/4885 |
| US-20160095938-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | KMT2A 634/4885EPHX2 124/4885MALT1 1122/4885 |
| US-20210299271-A1 | CONJUGATES COMPRISING CELL-BINDING AGENTS AND CYTOTOXIC AGENTS | PCNA, EPCAM, MKI67 | KMT2A 634/4885EPHX2 124/4885MALT1 1122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.